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Abstract
Background: Foot-and-mouth disease (FMD) is a highly contagious disease of livestock that causes severe economic loss in
susceptible cloven-hoofed animals. Although the traditional inactivated vaccine has been proved effective, it may lead to a
new outbreak of FMD because of either incomplete inactivation of FMDV or the escape of live virus from vaccine production
workshop. Thus, it is urgent to develop a novel FMDV vaccine that is safer, more effective and more economical than
traditional vaccines.
Methodology and Principal Findings: A recombinant silkworm baculovirus Bm-P12A3C which contained the intact P1-2A
and 3C protease coding regions of FMDV Asia 1/HNK/CHA/05 was developed. Indirect immunofluorescence test and
sandwich-ELISA were used to verify that Bm-P12A3C could express the target cassette. Expression products from silkworm
were diluted to 30 folds and used as antigen to immunize cattle. Specific antibody was induced in all vaccinated animals.
After challenge with virulent homologous virus, four of the five animals were completely protected, and clinical symptoms
were alleviated and delayed in the remaining one. Furthermore, a PD50 (50% bovine protective dose) test was performed to
assess the bovine potency of the subunit vaccine. The result showed the subunit vaccine could achieve 6.34 PD50 per dose.
Conclusion: The results suggest that this strategy might be used to develop the new subunit FMDV vaccine.
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Introduction
Foot-and-mouth disease (FMD) is an economically important
disease of domestic and wild cloven-hoof animals including cattle,
swine, goat, sheep and buffalo. It can result in great reduction of
productivity in adult animals and death in young animals. FMD is
endemic inparts ofAsia, Africa,the MiddleEastand South America
(with sporadic outbreaks in other ‘‘free areas’’). In countries affected
by the disease, livestock trade and animal products have been
impacted. Even in developed countries and areas, outbreak of FMD
would greatly affect the economy. In 2001, the outbreak of FMD in
England brought a loss of 8 billion dollars [1], and the consequent
occurrence in Holland killed 0.2 million animals [2]. In addition, the
1997outbreakinTaiwanbroughtalossofabout3.6billiondollarsto
its exports [3]. Therefore, controlling bath endemic and epidemic
FMD has become a global concern in livestock raising.
At present, vaccination is a major means of FMD control in
most endemic areas. The present method of FMDV vaccine
production is this: The virus is propagated in BHK-21 cell line,
concentrated, and chemically inactivated. Although the inactivat-
ed vaccine has been shown to be effective, it may lead to new
outbreaks of FMD because of either the incomplete inactivation of
FMDV in large-scale production or the escape of the live virus
from vaccine production workshops [4]. Therefore several
expression systems such as E.coli [5], transgenic plant [6], yeast
[7], adenovirus vector [8–12], vaccinia virus vector [13], and
DNA vaccine [14], have been used for expression of FMDV
antigen to prepare subunit vaccines. But such methods have
problems such as poor immunogenic capability or low efficiency.
Adenovirus based vaccine known for its best protective effects can
protect 5 of 5 vaccinated cattle, but this vaccine is still
unacceptable because of safety problem and preservation difficul-
ty. The baculovirus expression system, a valuable expression
system to produce virus-like particles, has successfully produced
many kinds of empty viral capsids [15,16], such as rabbit
hemorrhagic disease virus, Norwalk-like viruses,SARS and so on
[17,18,19]. Compared to the baculovirus expression system
(AcNPV-Sf cell), silkworm-baculovirus expression system has
distinct advantages [20,21]. First, expression levels in silkworm
are 50–1000 times higher than that in insect cell lines. Second,
silkworm don not have any pathogens that can cross infect with
vertebrates and animal serum is not needed to produce foreign
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are safer to vertebrates. In view of all these advantages, the
silkworm-baculovirus expression system was employed for expres-
sion of intact P1-2A, 3C coding regions of FMDV Asia I/HNK/
CHA/05. All five cattle that were vaccinated with diluted
expression antigen were induced specific antibody, four of which
were considered completely protected. Furthermore, the PD50
(50% bovine protective dose) value of the subunit vaccine was 6.34
in bovine potency test.
Results
Construction of the recombinant virus Bm-P12A3C
Intact P1-2A and 3C protease coding regions from FMDV Asia
I/HNK/CHA/05 strain were amplified by RT-PCR and inserted
into the transfer vector pVL1393 to generate plasmid pVL-
P12A3C. The plasmid was digested with BamHI / EcoRIt o
generate fragments of 2.3 kb and 10 kb, while fragments of 0.7 kb
and12 kb were generated with EcoRI / Bgl II. Based on the length
of these fragments, it was confirmed that the full target fragment
(P12A3C) was correctly incorporated into the transfer vector and
that the expression cassette was located downstream of polyhedrin
promoter. Sequence analysis indicated that the P12A3C was
3,024 bp containing full P1-2A and 3C genes and partial 2B,3B
genes.
Bm-N cell line was co-transfected with baculoviral transfer
plasmid pVL-P12A3C and linearized BmBacPAK-6 DNA. The
supernatant was collected 4 days post transfection as the viral stock
for screening of recombinant virus. Twenty four isolated viral
plaques from the plaque assays were cultivated in a 24-well plate
and were inoculated into silkworms. The plaque of recombinant
virus expressed at maximal activity was selected to purify. The
pure recombinant virus from the last round was used as stock virus
and confirmed to contain the full expression cassette. The
recombinant virus Bm-P12A3C was used to express FMDV
protein in cells or silkworm.
Expression of polyprotein in Bm-N cell
The expression of polyprotein in Bm-N cells was analyzed by
IFAT and sandwich-ELISA. IFAT pictures demonstrated that Bm-
N cells infected with Bm-P12A3C produced specific fluorescence,
while only very weak background fluorescence appeared in the
control cells (Fig. 1). This indicated that polyprotein was indeed
expressed in Bm-N cell. The sandwich-ELISA results indicated
that the FMDV antigen in Bm-P12A3C infected cells was
expressed at levels about equivalent to the positive control, but
was not detected in BmBacPAK-6 infected cell lysate.
Expression of polyprotein in silkworm
The Bm-P12A3C virus was inoculated 1,000 silkworms. The
dying silkworm’s haemolymph was collected (about 4–5 d post
infection, corresponding with rearing mean temperature about
25–27uC). Sandwich-ELISA was conducted to evaluate the
expressed antigen in silkworm. The results indicated that OD
value of the harvested haemolymph from silkworm infected by
Bm-P12A3C decreased as the dilution rate increased, which was
in good agreement with variation of positive control of FMDV
antigen. The expression yield was about 100 fold (positive
antigen: 1/32,0.964; expressed antigen in haemolymph: 1/4096,
0.995) more than the positive control (BHK-21 cell vaccine
which had a PD50 value of 3.6), but was not detectable in the
negative control (BmBacPAK-6 infected silkworm’s haemo-
lymph) (Fig. 2).
In order to determine the time course of expressed antigen in
silkworm and the optimum acquisition time for large scale’s
production, haemolymph from 10 silkworms was harvested every
12 h beginning at 60 hpi and stored at 220uC. Subsequently, the
haemolymph was diluted to 1000 folds for detection of expression
products (Fig. 3). There was a little at 60 hpi, and the
accumulation of recombinant products were dramatically in-
creased from 84 hpi and kept at the high levels during the late
phase of infection. So, expressed antigen could be harvested at
108–120 hpi (at the condition about the mean rearing tempera-
ture of 25uC).
The anti-FMDV antibody in cattle
Cattle were vaccinated by the vaccine prepared from 1/30
diluted expressed antigens (the quantity of antigen was about 3
folds of the BHK-21 cell vaccine). LPBE-antibody titer was
determined at 7, 14, 21 and 28 dpv following the LPBE method.
It was found that all five cattle vaccinated with Bm-P12A3C
antigen developed a detectable FMDV-antibody response at
7 dpv, and dramatically reached to high level at 14 dpv. By
21and 28 dpv, the antibody level was maintained at the same
level or higher, and reached to a titer of 360 in cattle No33 and
No50. In contrast, antibody level in the two control cattle
Figure 1. Expression of FMDV polypeptides in Bm-N cells was
analysed by IFAT. (A) Bm-N cells infected with Bm-P12A3C. (B) Bm-N
cells infected with BmBacPAK-6.
doi:10.1371/journal.pone.0002273.g001
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boosted (Table 1).
Furthermore, sera were analyzed for neutralizing antibodies
against FMDV (Table 2). While the two control cattle could not
develop any neutralization antibodies against FMDV, all five cattle
vaccinated with Bm-P12A3C antigen developed a FMDV-specific
neutralizing antibody response in 14pv and maintained at the
same level or higher in 28 dpv. The result was in agreement with
the LPBE-antibody titer.
Challenge with FMDV Asia I/HNK/CHA/05
All vaccinated cattle were challenged with 10,000 BID50 of Asia
I/HNK/CHA/05 at 28 dpv. Body temperature, mouth and feet
were observed consecutively for ten days to evaluate the incidence
of disease (Table 3). Four of the five cattle were considered
completely protected. Only one vaccinated cattle, No45, devel-
oped lesions. The lesions were detectable by 6 dpc and the clinical
signs were less severe compared to control group. By contrast,
vesicles developed in the control animals by 2 dpc at the sites of all
feet and mouth. This indicated that antigen produced in silkworm
could be effectively protective.
The result of PD50 test
The PD50 test was performed to assess the subunit vaccine potency
by following the bovine potency test protocol described by the OIE to
test the traditional inactivated FMD vaccines. In this research, the
result showed the vaccine potency of the batch immunized with the
expressed antigens reached 6.34 PD50 per dose (Table 4).
Figure 2. Expression of FMDV polypeptides in silkworm larvae was estimated by the sandwich-ELISA. The haemolymph was diluted
with two-fold series.
doi:10.1371/journal.pone.0002273.g002
Figure 3. The time courses of FMDV polyprotein expressed in
silkworm. The larval haemolymph was collected on ice every 12 h
from 60 hpi. The FMDV antigen in haemolymph was analyzed by the
sandwich-ELISA. The hemolymph was diluted with 1,000 folds dilution.
doi:10.1371/journal.pone.0002273.g003
Table 1. FMDV-specific antibody response after vaccination
with Bm-P12A3C’s.
Animal Vaccine
a
LPBE-
antibody
b dpv
c
number 27 7 14 21 28
33 Bm-P12A3C ,8 32 180 360 360
124 Bm-P12A3C ,8 2 09 09 09 0
122 Bm-P12A3C ,8 2 04 54 54 5
45 Bm-P12A3C ,8 2 09 09 09 0
50 Bm-P12A3C ,8 45 360 360 360
2 BmBacPAK-6 ,8 ,8 ,8 ,8 ,8
11 BmBacPAK-6 ,8 ,8 ,8 ,8 ,8
aBovines were vaccinated with vaccine prepared from 30 folds diluted
expressed antigens (Bm-P12A3C) or the control (BmBacPAK-6) and challenged
28 days later.
bFMDV-specific antibody titer reported as the serum dilution by LPBE method.
cDays postchallenge.
doi:10.1371/journal.pone.0002273.t001
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FMD still threatens world livestock production. Seven distinct
serotypes of FMDV have been identified, named A, O, C, Asia I,
SAT I, SAT and SAT with none cross immune protection
occurring between them. The FMDV serotype Asia which was
first isolated in Pakistan is epidemic within Southeast Asia and
Indian peninsula, disseminating among Near East, Middle East
and Far East [22]. In March 2005, FMDV serotype Asia was
found in HongKong (Asia I/HNK/CHA/05 strain). Subsequent-
ly, this type of the virus was reported from mainland of China in
April 2005[23]. The P1 sequence of Asia 1/HNK/CHA/05
isolate was aligned and compared with 9 reference sequences. The
result confirmed that Asia 1/HNK/CHA/05 has a high identity
with nine Asia I reference sequences from 85.9 to 92.6% [24].
Expression products of baculovirus expressing system are
generally considered to be well immunogenic and possess the
ability to assemble empty viral capsid. When the same FMDV
expression cassette were expressed in E.coli and baculovirus
expression system, the expression products from baculovirus
excels that from E.coli in terms of the immunogenic [25] and
protective effects [26]. Empty capsid comes into being only when
capsid precursor P1-2A, protease L and 3C coding region from
FMDV O1K serotype were all expressed in baculovirus expressing
system(AcMNPV-Sf cell). Truncated protease L can not be self-
cleaved from VP0. But, the expressed protease L is harmful to host
cell growth, reducing the expression efficiency [27]. In adenovirus
expression system, P12A3C expression cassette, including full
structure of P1-2A,3C and portion of 2B and 3B, can be expressed
and assembled into empty capsids [8]. Myristoylation of the animo
terminus of P1-2A is of great importance to the assembly of viral
particles [28]. It has been reported that the expression products of
AcMNPV-Sf cell can be myristoylated well [29]. Based on the
above studies, and using the design previously published by Mayr
et al [8], the P12A3C expression cassette of FMDV serotype Asia I
was constructed. After two sorting rounds of recombinant virus
and measurements of expression efficiency for more than 20 viral
clones, the over-expressed recombinant virus Bm-P12A3C was
obtained. It can express with very high efficiency in the
hyperexpression variety of silkworm (JY1). The specific antigen
produced per milliliter in silkworm haemolymph at least 100 folds
more than the BHK-21 cell vaccine which had a PD50 value of
3.6.
Because cattle are the most important economic and susceptible
cloven-hoof animal, we designed an experiment to verify whether
this produced antigen can be used for preparing a cattle FMD
vaccine. We followed the bovine potency test protocol described
by the OIE to test this subunit vaccine potency. We used 1/30
diluted dosage to vaccinate five cattle and two controls were
vaccinated with vaccine prepared from BmBacPAK-6’s. By two
weeks post vaccination, the antibody level of the five vaccinated
Table 2. Results of neutralizing antibody response against
FMDV after inoculation.
Animal #Vaccine
a
neutralizing
antibody
b dpv
c
number 27 7 14 21 28
33 Bm-P12A3C ,8 1 66 49 09 0
124 Bm-P12A3C ,8 8 64 64 64
122 Bm-P12A3C ,8 8 32 32 32
45 Bm-P12A3C ,8 8 32 32 32
50 Bm-P12A3C ,8 8 64 90 90
2 BmBacPAK-6 ,8 ,8 ,8 ,8 ,8
11 BmBacPAK-6 ,8 ,8 ,8 ,8 ,8
aBovines were vaccinated with vaccine prepared from 30 folds diluted
expressed antigens (Bm-P12A3C) or the control (BmBacPAK-6).
bFMDV-specific antibody titer reported as the serum dilution by neutralization
tests.
cDays postchallenge.
doi:10.1371/journal.pone.0002273.t002
Table 3. Protection and clinical signs in cattle after challenge with FMDV Asia I/HNK/CHA/05.
Animal number # vaccine
Days of onset of
pyrexia
a
Duration of
Pyrexia(days) Lesion scores
b Protection
c
33 Bm-P12A3C - - - +
124 Bm-P12A3C - - - +
122 Bm-P12A3C - - - +
45 Bm-P12A3C Day 6 2 2 -
50 Bm-P12A3C - - - +
2 BmBacPAK-6 Day 2 3 4+mouth -
11 BmBacPAK-6 Day 2 3 4+mouth -
aPyrexia defined as body temperature 40uC.
bThe lesion score is the number of feet on which the cattle exhibited.
cProtection was determined that cattle did not take on the clinical signs of FMD during observation period (10 days post-challenge).
doi:10.1371/journal.pone.0002273.t003
Table 4. The result of PD50 test.
Immunize dose Rate of protection (%) PD50
1 5/5 (100) 6.34
1/3 4/5 (80)
1/9 2/5 (40)
All of cattle were challenged with 10,000 BID50 of Asia I/HNK/CHA/05 after
vaccination by inoculating the equivalent of a total of 10,000 BID50 of Asia I/
HNK/CHA/05 intradermally into two sites on the upper surface of the tongue.
All cattle were observed for 10 days. Vaccinated animals are protected if they
do not develop lesions on the feet and areas other than the injection sites on
the tongue. Rate of protection (%)=number of cattle no lesions/total number
of cattle. The PD50 value was calculated by the Reed-Muench method.
doi:10.1371/journal.pone.0002273.t004
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but maintained thereafter two weeks, while the control group
maintained lower than titer 8. After virulent homologous virus
challenge, four of the five were considered protected, and one
delayed the disease and ease the clinical symptom, but two
unvaccinated cattle developed lesions on all the feet and in the
inside of mouth on the second day. Cell-mediated -immune
response was probably involved in the protection: that would
explain why animal 45 has the same neutralizing antibody titers as
122 but is not protected. This demonstrated that the expression
products from silkworm- baculovirus expression system were
immunogenic as well. Based on above result, we did the PD50 test
to assess the bovine potency of the subunit vaccine. When
employed for routine prophylactic use, the vaccine should contain
at least 3 PD50 per dose for cattle by OIE recommended. The
result showed the subunit vaccine potency could get 6.34 PD50 a
dose for cattle. This leads to a conclusion that it is feasible to use
the silkworm-baculovirus expression system for FMD vaccine
production.
Materials and Methods
Viruses and cell lines
FMDV Asia I/HNK/CHA/05 strain (GenBank accession
number EF149010) was propagated in BHK-21 cell line, isolated,
and preserved in Lanzhou Veterinary Research Institute of
Chinese Academy of Agriculture Sciences. The parental virus
BmBacPAK-6 (Chinese patent: 1242428), Bm-N cell line and
silkworm variety JY1 used for the experiment were maintained in
Biotechnology Research Institute of Chinese Academy of
Agriculture Sciences. The BmBacPAK-6 and recombinant virus
were maintained in Bm-N cells at 27uC in TC-100 insect medium
(Sigma) supplemented with 10% heat-inactivated fetal bovine
serum (Invitrogen).
Construction and screening of recombinant baculovirus
Genomic RNA was extracted from the viral supernatant with
RNeasy (Qiagen) and used immediately for cDNA synthesis.
cDNA synthesis was performed with Superscript II reverse
transcriptase (Invitrogen). PCR was used to amplify the Intact
P1-2A and 3C protease coding regions from the cDNA using two
pairs of specific primer:
Forward primer for P1-2A: 59-ATAGGATCCACCATGG-
GAGCCGGGCAATCCAGCC-39 (BamH I site was introduced)
Reverse primer for P1-2A 59-CGCGAATTCTGACATGT
CCTCCTGCATCTGGTTG-39 (EcoR I site was introduced)
Forward primer for 3C:59-GCGGAATTCAAGAAACCT
GTCGCTTTGAAAGT-39 (EcoR I site was introduced)
Reverse primer for 3C:59ATAAGATCTCTACTCGTGG
TGTGGTTCGGGAT-39 (Bgl II site was introduced)
The PCR products were separated by 1% Agarose gel
electrophoresis. The target fragments of P1-2A and 3C were
inserted into baculoviral transfer vector pVL1393 using BamHI /
EcoR I and EcoRI / Bgl II sites following the routine protocols to
generate a transfer plasmid. The whole P1-2A and 3C coding
regions in transfer plasmid was sequenced and named pVL-
P12A3C.
The baculoviral transfer plasmid pVL-P12A3C was co-trans-
fected with linearized Bm-BacPAK6 DNA into Bm-N cells by
liposome-mediated method using transfection reagent lipofectamin
2000 (Invitrogen) [30]. The co-transfection supernatant was
subject to plaque assays to screen the individual viral plaques.
PCR amplification was conducted to confirm that the P1-2A and
3C genes had been incorporated into the baculoviral genome.
Primers were designed as follows: Sense: 59-ACTGTTTTCG-
TAACAGTTTTGTAA-39 and Reverse: 59-CTACTCGTGGT
GTGGTTCGGGAT-39. Another two rounds of screen were
performed and the pure recombinant virus was used to generate
high titer viral stocks for expression.
Expression of FMDV polyprotein in Bm-N cells
The expression of FMDV polyprotein in Bm-N cells infected
with Bm-P12A3C was analyzed by immunofluorescence test
(IFAT) and sandwich-ELISA. The Bm-P12A3C was multiplied
in Bm-N cells. Bm-N cells (2.0610
5) were cultured on cover slips
and inoculated at a MOI of 10 pfu with Bm-P12A3C. After
48 hours post infection (hpi), IFAT was conducted to analyze the
expression of FMDV proteins. Cells were then rinsed with PBS for
1 or 2 times and fixed in 100% cold acetone (220uC for 30 min).
Samples were incubated with rabbit serum against FMDV (37uC
for 30 min) in humid box, washed with PBS for five times, and
then stained with fluorescein-conjugated goat anti-rabbit serum at
37uC for 30 min. The cover slips were coated with glycerin and
observed on an Olympus fluorescence microscope. Bm-N cells
infected with BmBacPAK-6 were used as control.
When Bm-N cells infected with Bm-P12A3C were partial
floating, they were detached and collected (about 72 hpi), the cells
pellet was freezed and thawed at -70/37uC in PBS for three times
and centrifuged at 10,000g for 5 min at 4uC. The supernatant was
tested using the sandwich-ELISA method. 96-well plat-bottomed
plates (Costar) were coated with the rabbit serum against FMDV
overnight at 4uC and blocked with defatted milk powder for 1h.
Then the plates were washed five times. FMDV antigen (from the
vaccine which had a PD50 value of 3.6), lysates of Bm-N cells with
Bm-P12A3C and BmBacPAK-6 infected were diluted in a two-
fold series and incubated at 37uC for 1h. Subsequently, the plates
were washed thoroughly and guinea pig sera against FMDV was
added to each well. The plates were incubated at 37uC for 1 h,
and then rabbit anti-guinea pig IgG peroxidase conjugate (Sigma)
at 1:10000 dilution was added and reacted at 37uC for 1 h.
Substrate (0.05% H2O2 plus orthophenylene diamine) was added,
reacted for 15 minutes and stopped by the addition of 1M
sulphuric acid. Absorbance was determined at 492 nm.
Expression of polyprotein in silkworm
Early fifth-instar silkworms were infected with the recombinant
virus at about 10
5 pfu per larva. The dying silkworm’s
haemolymph was collected on ice and stored at 220uC for
sandwich-ELISA.
The infected silkworm’s haemolymph was collected every 12 h
starting at 60 hpi for determining the expression course of target
antigen.
Detection of specific antibody by LPBE and serum
neutralization test (SNT)
Silkworm haemolymph was lysed ultrasonically and cell debris
was removed by centrifugation. The diluted supernatant was used
to produce vaccine. Liquid-phase blocking ELISA(LPBE)(http://
www.oie.int/eng/normes/MMANUAL/A_00024.htm) was per-
formed to determine the antibody titer for screening of candidate
cattle according to the standard method of World Organization
for Animal Health, Office International desEpizooties (OIE)
before vaccination. Candidates with a potency lower than 8 were
housed in disease-secure isolation facilities in Lanzhou Veterinary
Research Institute. Detection kit was prepared by Lanzhou
Veterinary Research Institute. Seven cattle (6–8 months old) were
immunized by intramuscular inoculation at the site in the neck.
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P12A3C’s, while two control cattle were vaccinated with the same
dose of vaccine with BmBacPAK-6’s.
Cattle serum were collected at 7, 14, 21and 28 days
postvaccination (dpv). Antibody against FMDV was detected by
LPBE method (as above) and SNT.
For SNT, the sera was diluted in DMEM as two-fold in a 96-
well flat-bottomed tissue culture plates (Castor, USA). Virus
suspension with a titer of 100 TCID50 in 50 ul was added to each
sera well and the mixture was incubated for 1 h at 37uC and 5%
CO2. 50 ul of BHK-21 cell suspension (1.5610
6 ml
21) was added
to each well and incubated for 4–5 days. Appropriate serum, virus
and cell control were included in this test. The plates were
observed via microscope for cytopathic effect.
Challenge with virulent homologous FMDV
According to the descriptions by standard protocol of OIE
(http://www.oie.int/eng/normes/MMANUAL/A_00024.htm),
all animals were challenged by intradermal inoculation at two sites
in the tongue with 10,000 bovine infectious doses (BID50) of Asia
I/HNK/CHA/05 at 28 dpv. The body temperature of the
animals was monitored daily. The restrained animals were
carefully examined in the mouth, and feet every day for the first
10 days after challenge.
PD50 test
We followed the bovine potency test protocol described by the
OIE to test this subunit vaccine potency. Three groups of five
cattle per group and a control group of two non-vaccinated
animals were vaccinated. The vaccinated groups were admin-
i s t e r e dd i f f e r e n td o s e s( 1d o s e ,1 / 3d o s e ,1 / 9d o s e ) o ft h es u b u n i t
vaccine prepared from diluted expression products and all
animals were challenged 3 weeks after vaccination with 10,000
BID50 of Asia I/HNK/CHA/05 to the vaccine under test by
intradermal inoculation into two sites on the upper surface of
the tongue. The animals were observed daily for 10 days after
challenge for clinical signs of FMD. Control animals developed
lesions on at least three feet. Unprotected animals showed
lesions at sites other than the tongue. From each animal
protected in each group, the PD50 (50% bovine protective dose)
content of the vaccine was calculated based on the Reed-
Muench method.
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